Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
16.14
+0.24 (1.51%)
Jun 16, 2026, 10:12 AM EDT - Market open
Rallybio Revenue
Rallybio had revenue of $212.00K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $858.00K, up 1.18% year-over-year. In the year 2025, Rallybio had annual revenue of $858.00K with 34.91% growth.
Revenue (ttm)
$858.00K
Revenue Growth
+1.18%
P/S Ratio
98.03
Revenue / Employee
$61,286
Employees
14
Market Cap
85.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 858.00K | 222.00K | 34.91% |
| Dec 31, 2024 | 636.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRLYB News
- 15 days ago - Rallybio to acquire Avenzo Therapeutics through merger transaction - TheFly
- 15 days ago - Rallybio Transcript: M&A announcement - Transcripts
- 15 days ago - Rallybio Press release: M&A announcement - Filings
- 15 days ago - Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement - Business Wire
- 3 months ago - Rallybio Annual report: Q4 2025 - Filings
- 3 months ago - Rallybio, Candid Therapeutics announce merger agreement - TheFly
- 3 months ago - Rallybio Transcript: M&A announcement - Transcripts
- 3 months ago - Rallybio Press release: M&A announcement - Filings